But current methods remain challenging. Dr. Amir Jahanian-Najafabadi from Constructor University has been conducting a series of studies exploring the use of advanced computational models applied on ...
The interplay between cortisol, inflammation, and disease underscores the need for effective stress management to enhance ...
Depression and anxiety affect approximately 40% of adults with chronic pain, according to a massive new systematic review and ...
Mind Medicine (MNMD) announced its Q4 financials and indicated it is making strides in developing innovative treatments for brain health ...
Zacks Investment Research on MSN2d
JNJ Halts Development of Depression Drug Over Efficacy ConcernsJohnson & Johnson JNJ decided to discontinue the Phase 3 VENTURA development program, which is evaluating aticaprant as an ...
Clinical Trials Arena on MSN2d
J&J drops Phase III MDD programme due to lack of efficacyJ&J said it plans to “explore future development opportunities for aticaprant in other areas of high unmet need”. A statement ...
Among 347,468 individuals who had lived with persistent pain for over 3 months, clinical symptoms of depression and anxiety ...
NIH technology transfer offices have been barred from filing new patent applications and restricted from licensing existing ...
Johnson & Johnson (JNJ) announced last night its decision to discontinue the Phase 3 VENTURA development program evaluating aticaprant as ...
Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...
Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion ...
Menopause can worsen symptoms of bipolar disorder. In rare cases, it may trigger bipolar disorder. Menopause is a factor when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback